Alnylam Pharmaceuticals, Inc. $ALNY Position Lessened by KBC Group NV

KBC Group NV lowered its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 94.1% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,524 shares of the biopharmaceutical company’s stock after selling 327,670 shares during the quarter. KBC Group NV’s holdings in Alnylam Pharmaceuticals were worth $6,791,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. First Horizon Corp lifted its stake in Alnylam Pharmaceuticals by 20.7% in the fourth quarter. First Horizon Corp now owns 163 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 28 shares during the last quarter. Yousif Capital Management LLC grew its position in shares of Alnylam Pharmaceuticals by 1.8% during the fourth quarter. Yousif Capital Management LLC now owns 1,676 shares of the biopharmaceutical company’s stock worth $666,000 after acquiring an additional 29 shares during the last quarter. Daiwa Securities Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 0.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock worth $4,220,000 after acquiring an additional 35 shares during the period. Golden State Wealth Management LLC increased its holdings in shares of Alnylam Pharmaceuticals by 100.0% in the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 36 shares during the period. Finally, Coldstream Capital Management Inc. lifted its position in Alnylam Pharmaceuticals by 2.4% in the 3rd quarter. Coldstream Capital Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $748,000 after purchasing an additional 38 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Insider Activity at Alnylam Pharmaceuticals

In related news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the sale, the director owned 1,582 shares of the company’s stock, valued at $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Bank of America reduced their target price on shares of Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating for the company in a research note on Tuesday, July 14th. HC Wainwright lifted their price target on Alnylam Pharmaceuticals from $470.00 to $485.00 and gave the company a “buy” rating in a report on Monday, July 13th. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Truist Financial decreased their price objective on Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating for the company in a report on Monday, July 13th. Finally, Wall Street Zen cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 7th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $452.13.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $266.99 on Thursday. The firm has a market capitalization of $35.65 billion, a PE ratio of 72.95 and a beta of 0.27. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94. The firm has a 50-day moving average price of $293.02 and a 200 day moving average price of $317.88. Alnylam Pharmaceuticals, Inc. has a 52-week low of $264.21 and a 52-week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, topping analysts’ consensus estimates of $0.87 by $1.12. The company had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. Alnylam Pharmaceuticals’s revenue was up 96.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.44) EPS. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.35 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.